

I-07 IFNAR SIGNALLING PROMOTES MICROGLIA DYSFUNCTION IN SLE

¹Allison R Bialas*, ¹Abhishek Das, ¹Jessy Presumey, ¹Cees van der Poel, ²Luka Mesin, ³Ronald Herbst, ²Gabriel Victoria, ¹Michael Carroll. ¹Program in Cellular and Molecular Medicine, Boston Children's Hospital; ²Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; ³Department of Research, MedImmune, LLC, Gaithersburg, MD

10.1136/lupus-2016-000179.72

Background One of the most prevalent, but least understood aspects of SLE is the fact that patients commonly develop neuropsychiatric symptoms, a condition referred to as central nervous system (CNS) lupus. The mechanisms driving neuropsychiatric disorders remain enigmatic; moreover, CNS lupus symptoms are variable and complicated by the systemic nature of the disease. The molecular mechanisms of CNS lupus thus remain a major gap in the lupus field. Interestingly, CNS lupus patients can show reduced grey matter volume, suggestive of neuron or synapse loss; however, the mechanisms underlying this neuron and synapse loss have yet to be fully explored. We looked to other CNS diseases for mechanistic clues relevant for CNS lupus. In Alzheimer's disease, synapse loss is an early event and microglia have been identified as major mediators of the process. Type I interferon signalling has also emerged as a modulator of microglia activation and is commonly elevated in SLE patients. Therefore, we hypothesise that type I interferon may stimulate microglia dysfunction and promote aberrant microglia-mediated synapse loss.

Materials and methods We addressed this hypothesis using genetic and pharmacological approaches to block interferon alpha receptor (IFNAR) signalling in lupus models (564 Igi and NZB/W). Immunohistochemistry based assays were used to determine microglia activation state combined with RNAseq to characterise microglia gene expression changes. Flow cytometry, confocal, and electron microscopy were used to assay microglia engulfment of neuronal material and synapse density.

Results Gene expression analysis of microglia isolated from lupus mice identified significant upregulation of interferon stimulated genes and genes associated with microglia function. Consistent with these data, significant increases were observed in activated microglia in lupus mice relative to wild type littermates. Moreover, reminiscent of early development where microglia are important in synaptic pruning, microglia could be found engulfing neuronal material. In MX1 reporter mice, MX1+ microglia were more reactive than MX1- microglia in lupus mice and showed increased engulfment. Lupus mouse models also showed reduced synapse density at ages concurrent with increased microglia engulfment, suggesting aberrant microglia pruning of synapses. Treatment in vivo with anti-interferon receptor antibody protected against reactive microglia and engulfment of neuronal material. Injection i.v. with IFN- α or - β was sufficient to stimulate microglia engulfment of neuronal material.

Conclusion Taken together, these results suggest that type I interferon is necessary and sufficient to stimulate microglia dysfunction in SLE and identifies a novel potential mechanism promoting synapse loss and neuropsychiatric symptoms in CNS lupus patients.

Clinical Trials

CT-01 PHASE IB STUDY OF IMMU-115 (HUMANISED ANTI-CD74 ANTIBODY) TARGETING ANTIGEN PRESENTING CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

¹Daniel J Wallace*, ²William A Wegener, ²Heather Horne, ²David M Goldenberg. ¹Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ²Immunomedics, Inc., Morris Plains, NJ, USA


10.1136/lupus-2016-000179.73

Background IMMU-115 (milatuzumab), a humanised antibody targeting the CD74 antigen on antigen-presenting cells (APC), is being investigated in haematological malignancies. Since dysregulation of APCs may occur in autoimmunity, IMMU-115 could potentially help control disease activity in SLE. Following promising preclinical studies, IMMU-115 was reformulated for convenient administration by subcutaneous (SC) injection, and this initial study was undertaken.

Materials and methods Phase I, dose-escalation study in adults with SLE (ACR revised criteria) and positive ANA (titer $\geq 1:80$), with moderate disease activity but not severe flares (at least 2 BILAG B's, but no A's) despite ≥ 5 mg/day prednisone. Background lupus medications continue with SC IMMU-115 administered weekly for 4 consecutive weeks. Disease activity is assessed by BILAG2004 and SELENA-SLEDAI every 4 weeks until week 24

Results Ten patients (9F/1 M; median age, 37; median disease-duration, 7 years) have now completed dose level one, receiving 250 mg doses of IMMU-115 injected once-weekly for 4 weeks. They were on prednisone (5–20 mg/day, n = 10), antimalarials (n = 7), and immunosuppressives (n = 2) with mean SLEDAI 9.6 and BILAG-B activity in the musculoskeletal (n = 10), mucocutaneous (n = 9), cardiorespiratory (n = 1), and renal (n = 1) body systems. All patients improved in ≥ 1 body system, eliminating most musculoskeletal B's (9/10, 90%) and mucocutaneous B's (7/9, 78%) by week 8, with the single cardiorespiratory B eliminated by week 20, and the renal B vacillating between B and C over the study. Four patients flared post-treatment with new B-level disease at weeks 8, 12 and 20 (all cardiorespiratory) and week 24 (neuropsychiatric). Following treatment, mean total BILAG (scored using B = 5, C = 1, D/E = 0) decreased 43% and mean SLEDAI decreased 54%, both measures remaining decreased through week 24 (Figure 1). Adverse events were Grade 1–2 (mild-moderate) and predominantly injection site (n = 7) or constitutional/flu-like (n = 9) reactions managed with supportive medication (steroids, antihistamines, anti-pyretics). Routine safety and other laboratories (B/T cells, monocytes, dendritic cells, serum immunoglobulins, cytokines, ANA, other autoantibodies, CRP, C3) were unremarkable. One patient developed anti-IMMU-115 antibodies of uncertain clinical significance, resolving within 3 months.

Conclusions IMMU-115 showed evidence of therapeutic efficacy with acceptable toxicity already at the first dose level, including suppression of disease activity extending 24 weeks in most patients. To confirm these results, further dose escalation



Abstract CT-01 Figure 1 Mean total BILAG and mean SLEDAI at baseline and then every 4 weeks until week 24

was suspended with patients currently being randomised under double-blind conditions to receive treatment with 250 mg doses, a reduced dose of 100 mg, or placebo control.

Acknowledgements Supported in part by U.S. Department of Defense Grant W81XWH-13-1-0392.

Trial Registration Clinicaltrials.gov identifier: NCT01845740

CT-02

FEATURES OF PATIENTS SCREENED FOR CALIBRATE (RITUXIMAB PLUS CYCLOPHOSPHAMIDE FOLLOWED BY BELIMUMAB FOR THE TREATMENT OF LUPUS NEPHRITIS); HYPOGAMMAGLOBULINEMIA IS FREQUENT IN PATIENTS WITH MARKED ELEVATION OF URINARY PROTEIN

¹Cynthia Aranow*, ¹Betty Diamond, ²David Wofsy, ³Margaret Byron, ⁴Dawn Smilek, ⁵Linna Ding, ⁴Patti Tosta, ⁴Kristin Ryker, ⁵Wendy Gao, ²Maria Dall'Era. ¹Feinstein Institute, USA; ²University of California San Francisco, USA; ³Rho Federal Systems, Inc., USA; ⁴The Immune Tolerance Network, NIAID, USA; ⁵National Institute of Allergy and Infectious Diseases, NIH, USA

10.1136/lupus-2016-000179.74

Background Treatment options for lupus nephritis (LN) are limited by imperfect efficacy and multiple toxicities; new approaches are needed. Autoreactive B cells are attractive therapeutic targets given their pathogenic role in LN. However, a prospective randomised LN trial of B cell depletion with rituximab did not demonstrate improved efficacy. It is likely that the high levels of BAFF that exist following B cell depletion facilitate the maturation of autoreactive B cells. This autoreactivity may contribute to the limited clinical response. We have hypothesised that administration of an anti-BAFF reagent following B cell depletion will result in an enhanced, sustained clinical response.

Materials and methods CALIBRATE is a trial assessing the safety of belimumab following B cell depletion in patients with non-naïve LN (relapsed LN or LN that is resistant to therapy). Forty subjects will receive treatment with rituximab and cyclophosphamide; 20 will be randomised to receive belimumab for up to 1 year, 20 will receive no other therapy except for glucocorticoids. Efficacy and mechanistic outcomes at 1 and 2 years will also be evaluated. Given the ability of both rituximab and belimumab to depress serum IgG levels, levels of IgG are determined at

screening in order to follow the combined effect of rituximab and belimumab on IgG and risk of infection during the CALIBRATE trial. We now present the characteristics of subjects screened for this study.

Results CALIBRATE has screened 27 patients. Demographic and clinical features at screening are shown in Table 1. Patients with a Up/c ratio >3 were 16 times (95% CI: 1.4, 767.3) more likely to have IgG levels ≤450 mg than patients with Up/c ≤3. Furthermore Up/c correlated inversely with serum IgG ($r = -0.524$, $p = 0.0050$).

Abstract CT-02 Table 1 Demographic and clinical features of patients screened for the CALIBRATE study

Age, years mean (SD)	30.2 (8.29)
Gender N (%)	
Male	4 (14.8)
Female	23 (85.2)
Race N (%)	
White	10 (37.0)
Black	7 (25.9)
Other/Unknown	10 (37.0)
ISN Class N (%)	
Class III	2 (7.4)
Class IV	5 (18.5)
Class V + III	5 (18.5)
Class V + IV	15 (55.6)
Up/c r ratio mean (SD)	3.99 (3.333)
Up/c ratio > 3 N (%)	14 (51.9)
Up/c ratio ≤ 3 N (%)	13 (48.1)
Serum IgG mean (SD)	938.26 (547.684)
Hypogammaglobulinemia (IgG ≤ 450) N (%)	9 (33.3)
IgG ≤ 450 with Up/c ratio > 3 N (%)	8 (57.1)
IgG ≤ 450 with Up/c ratio ≤ 3 N (%)	1 (7.7)

Conclusions Physicians caring for lupus patients do not routinely measure IgG, even when considering initiation of rituximab or belimumab, therapies known to reduce serum IgG levels. We report that 33% of patients with non-naïve LN and >50% of patients with Up/c >3 are hypogammaglobulinemic. Transient